Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins
June 23, 2020
By: Ted Mathias and Rebecca Clegg
BioProcess Online / Biosimilar Development
BioProcess Online and Biosimilar Development published "Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins," an article written by Axinn partnerTed Mathias and associate Rebecca Clegg.
Click to access the article on BioProcess Online and Biosimilar Development.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
California's Crackdown on Algorithmic Pricing
Axinn Viewpoints
Antitrust
American Investment Council’s General Counsel Day
Speaking Engagement
Antitrust
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials

